Tranexamic acid formulations
View Patent ↗Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.
1. A tranexamic acid tablet formulation, comprising:
tranexamic acid or a pharmaceutically acceptable salt thereof; and
a modified release material, wherein the modified release material comprises a polymer selected from the group consisting of hydroxyalkylcelluloses, alkylcelluloses, cellulose ethers, partial esters thereof, and mixtures thereof;
wherein the modified release material is present in the formulation in an amount from about 10% to about 35% by weight of the formulation;
wherein the formulation provides an in-vitro dissolution release rate of the tranexamic acid or pharmaceutically acceptable salt thereof, when measured by the USP 27 Apparatus Type II Paddle Method @ 50 RPM in 900 ml water at 37±0.5° C., of less than about 70% by weight tranexamic acid or pharmaceutically acceptable salt thereof released at about 45 minutes, and about 100% by weight tranexamic acid or pharmaceutically acceptable salt thereof released by about 120 minutes; and
wherein each tablet of the formulation provides a dose of about 650 mg of tranexamic acid.
2. The tranexamic acid formulation of claim 1 , wherein the formulation provides a mean in-vitro dissolution release rate of the tranexamic acid or pharmaceutically acceptable salt thereof, when measured by the USP 27 Apparatus Type II Paddle Method @ 50 RPM in 900 ml water at 37±0.5° C., of about 15% to about 29% by weight tranexamic acid or pharmaceutically acceptable salt thereof released at about 15 minutes, about 56% to about 69% by weight tranexamic acid or pharmaceutically acceptable salt thereof released at about 45 minutes, and about 89% to about 100% by weight tranexamic acid or pharmaceutically acceptable salt thereof released at about 90 minutes.
3. The tranexamic acid tablet formulation of claim 1 , wherein the tablet is a matrix tablet which comprises a pregranulated drug mixed together with the modified release material.
4. The tranexamic acid tablet formulation of claim 1 , wherein the modified release material comprises a hydroxyalkylcellulose or a cellulose ether.
5. The tranexamic acid tablet formulation of claim 1 , wherein the modified release material comprises hydroxypropylmethylcellulose.
6. The tranexamic acid tablet formulation of claim 1 , wherein the modified release material is present in an amount of about 15% by weight of the formulation.
7. The tranexamic acid tablet formulation of claim 5 , wherein the modified release material is present in an amount of about 15% by weight of the formulation.
8. The tranexamic acid tablet formulation of claim 1 , wherein a single administration of the formulation comprising a dose of 1300 mg of tranexamic acid provides a mean maximum plasma concentration (C max ) of tranexamic acid in a range from about 9 mcg/ml to about 14.5 mcg/ml following the administration.
9. The tranexamic acid tablet formulation of claim 1 , wherein administration of the formulation comprising a dose of 1300 mg of tranexamic acid three times daily provides a mean maximum plasma concentration (C max ) of tranexamic acid in a range from about 12.5 mcg/ml to about 25 mcg/ml after multi-dose administration.
10. The tranexamic acid tablet formulation of claim 1 , wherein said formulation provides a mean T max at from about 2 hours to about 3.5 hours after single dose oral administration.
11. A tranexamic acid tablet formulation, comprising:
tranexamic acid or a pharmaceutically acceptable salt thereof; and
an effective amount of a modified release material, wherein the modified release material comprises a polymer selected from the group consisting of hydroxyalkylcelluloses, alkylcelluloses, cellulose ethers, partial esters thereof, and mixtures thereof;
wherein the modified release material is present in the formulation in an amount from about 10% to about 35% by weight of the formulation;
wherein the formulation releases from about 10% to about 25% by weight tranexamic acid or pharmaceutically acceptable salt thereof every 15 minutes when measured in vitro utilizing the USP 27 Apparatus Type II Paddle Method @ 50 RPM in 900 ml water at 37±0.5° C. such that about 100% of tranexamic acid or pharmaceutically acceptable salt thereof is released by about 120 minutes; and
wherein each tablet of the formulation provides a dose of about 650 mg of tranexamic acid.
12. The tranexamic acid tablet formulation of claim 1 , wherein administration of the formulation comprising a dose of 1300 mg of tranexamic acid three times daily provides a mean maximum plasma concentration (C max ) of about 10 mcg/ml to about 20 mcg/ml after multi-dose administration.
13. The tranexamic acid tablet formulation of claim 1 , wherein a single administration of the formulation comprising a dose of 1300 mg of tranexamic acid provides a mean maximum plasma concentration (C max ) of tranexamic acid in a range from about 9 mcg/ml to about 17.5 mcg/ml.
14. The tranexamic acid tablet formulation of claim 5 , wherein the hydroxypropylmethylcellulose is present in an amount of about 10% to about 35% by weight of the formulation.
15. The tranexamic acid tablet formulation of claim 14 , wherein the hydroxypropylmethylcellulose is present in an amount of about 15% by weight of the formulation.
16. A tranexamic acid tablet formulation, comprising:
tranexamic acid or a pharmaceutically acceptable salt thereof; and
hydroxypropylmethylcellulose in an amount from about 10% to about 35% by weight of the formulation;
wherein the formulation provides an in-vitro dissolution release rate of the tranexamic acid or pharmaceutically acceptable salt thereof, when measured by the USP 27 Apparatus Type II Paddle Method @ 50 RPM in 900 ml water at 37±0.5° C., of less than about 70% by weight tranexamic acid or pharmaceutically acceptable salt thereof released at about 45 minutes, and about 100% by weight tranexamic acid or pharmaceutically acceptable salt thereof released by about 120 minutes; and
wherein each tablet of the formulation provides a dose of about 650 mg of tranexamic acid.
17. The tranexamic acid tablet formulation of claim 16 , wherein the hydroxypropylmethylcellulose is present in an amount of about 15% by weight of the formulation.
18. A tranexamic acid tablet formulation according to claim 11 , comprising:
tranexamic acid or a pharmaceutically acceptable salt thereof; and
hydroxypropylmethylcellulose in an amount from about 10% to about 35% by weight of the formulation;
wherein the formulation releases from about 10% to about 25% by weight tranexamic acid or pharmaceutically acceptable salt thereof every 15 minutes when measured in vitro utilizing the USP 27 Apparatus Type II Paddle Method @ 50 RPM in 900 ml water at 37±0.5° C. such that about 100% of tranexamic acid or pharmaceutically acceptable salt thereof is released by about 120 minutes; and
wherein each tablet of the formulation provides a dose of about 650 mg of tranexamic acid.
19. The tranexamic acid tablet formulation of claim 18 , wherein the hydroxypropylmethylcellulose is present in an amount of about 15% by weight of the formulation.